Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus MECLAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus MECLAN.
ACTICLATE CAP vs MECLAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic